Abstract 294P
Background
We aimed to assess the safety and preliminary efficacy of cisplatin every 3 weeks in concurrent chemoradiation in cervical cancer in the era of modern radiotherapy techniques such as IMRT/VMAT.
Methods
This is a single-arm phase 2 clinical trial which included patients with stage IB3-IVA cervical cancer at Vietnam National Cancer Hospital. Neuroendocrine carcinoma was excluded. Patients were treated with definitive chemoradiotherapy with cisplatin 75mg/m2, day 1, 22 and 43 concurrently with external beam radiotherapy and brachytherapy. Treatment completion rate, response rate and toxicities were assessed.
Results
A total of 38 patients were included, with a mean age of 53.3 years (range 33-71). The mean tumor size was 4.31 ± 0.87 cm. Stage IB3, II and III accounted for 2.6%, 44.7% and 52.6% respectively. Thirty-seven patients (97.3%) completed planned treatment protocol, with the mean total time of radiation therapy of 49.8 ± 5.9 days. At 1 month after treatment, the complete clinical response rate was 84.2% (32/38 patients), partial response was recorded in 4 patients with stage IIIC1 and 2 patients with stage IIB. Among these 6 patients, 4 cases had complete response at 3 months after treatment. Grade 3 toxicity included neutropenia (15.8%) and vomiting (13.2%), no febrile neutropenia or life-threatening toxicities were recorded.
Conclusions
Concurrent chemoradiation with cisplatin every 3 weeks is a safe and feasible therapy for locally advanced cervical cancer and might be suitable for places with shortage of facilities and human resources in chemotherapy infusion unit. A larger randomized controlled trial should be done to confirm the efficacy of the 3-weekly schedule.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract